SELLAS Life Sciences (SLS) Tax Provisions (2013 - 2019)
SELLAS Life Sciences (SLS) posted quarterly Tax Provisions of -$81000.0 for Q4 2019, up 94.74% year-over-year from -$41593.1 in Q4 2018, and up 94.74% quarter-over-quarter from -$1.5 million in Q4 2018.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Tax Provisions (2013 - 2019) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Tax Provisions for 4 consecutive years, with -$81000.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Tax Provisions rose 94.74% year-over-year to -$81000.0; the TTM figure through Dec 2019 stood at -$1.6 million (down 24.29% YoY), while the FY2021 annual figure was -$237000.0, down 1294.12% from the prior year.
- Tax Provisions rose to -$81000.0 in Q4 2019 per SLS's latest filing, from -$1.5 million in the prior quarter.
- Across five years, Tax Provisions topped out at $163000.0 in Q2 2018 and bottomed at -$1.5 million in Q4 2018.
- Historically, Tax Provisions has averaged -$201000.0 across 3 years, with a median of $68000.0 in 2017.
- Annual changes were most pronounced in 2018 — Tax Provisions slumped 2210.96% — and 2019, when it jumped 94.74%.
- SELLAS Life Sciences' Tax Provisions stood at $73000.0 in 2017, then plunged by 2210.96% to -$1.5 million in 2018, then surged by 94.74% to -$81000.0 in 2019.
- Business Quant data shows SLS's Tax Provisions at -$81000.0 in Q4 2019, -$1.5 million in Q4 2018, and $163000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.90 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -81,000.00 |
| Dec 31, 2018 | -1.54 Mn |
| Jun 30, 2018 | 163,000.00 |
| Dec 31, 2017 | 120,000.00 |
| Sep 30, 2017 | 63,000.00 |
| Jun 30, 2017 | 117,000.00 |
| Dec 31, 2013 | 1.11 Mn |
| Sep 30, 2013 | 1.16 Mn |
| Jun 30, 2013 | 1.54 Mn |
| Mar 31, 2013 | -2.76 Mn |